Services

Toxicology

Pharmacology

Animal Model Development

Medical Device Testing

In Vitro Screening

Custom Assay Development

Vivarium Rental

Histology

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Species

Non-human Primates

Dogs

Minipigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Careers

Request a Quote

Logo
☰
  • Services ⌄
    • Toxicology
    • Pharmacology
    • Animal Model Development
    • Medical Device Testing
    • In Vitro Screening
    • Custom Assay Development
    • Vivarium Rental
    • Histology
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Minipigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Careers
    • Request a Quote

Court Blocks Sales of Unapproved Sexual Enhancement Products

  • Post author:Sam
  • Post published:August 30, 2018
  • Post category:Drug Industry Daily

The U.S. District Court for the District of New Jersey issued a permanent injunction barring online distributor Just Enhance from illegally selling sexual enhancement products on more than 100 websites.…

Continue ReadingCourt Blocks Sales of Unapproved Sexual Enhancement Products

EU Task Force Outlines Priorities for Drug Shortage Prevention

  • Post author:Sam
  • Post published:August 30, 2018
  • Post category:Drug Industry Daily

A European Union task force released a two-year plan on Wednesday to prevent or deal with drug shortages in the region. Source: Drug Industry Daily

Continue ReadingEU Task Force Outlines Priorities for Drug Shortage Prevention

CMS: Part D Plans Will Allow Indication-Based Formularies in 2020

  • Post author:Sam
  • Post published:August 30, 2018
  • Post category:Drug Industry Daily

In the latest CMS move aimed at reducing drug prices, Administrator Seema Verma released new guidance on how Part D plan sponsors can negotiate formulary coverage based on specific indications…

Continue ReadingCMS: Part D Plans Will Allow Indication-Based Formularies in 2020

FDA Updates Investigation on Valsartan Impurities, Expands Recall

  • Post author:Sam
  • Post published:August 30, 2018
  • Post category:Drug Industry Daily

FDA Commissioner Scott Gottlieb announced more recalls Thursday in the FDA’s ongoing investigation into contaminated valsartan products and said the impurity may be a byproduct of the API manufacturing process.…

Continue ReadingFDA Updates Investigation on Valsartan Impurities, Expands Recall

Indian API Manufacturer Cited for Investigative Deficiencies

  • Post author:Sam
  • Post published:August 29, 2018
  • Post category:Drug Industry Daily

The FDA called out Indian API manufacturer Vamsi Labs for failing to complete investigations at its Solapur, Maharashtra facility, including one of API batches shipped to the U.S. Source: Drug…

Continue ReadingIndian API Manufacturer Cited for Investigative Deficiencies

FDA to Replace Guidance on Developing New Pain Drugs

  • Post author:Sam
  • Post published:August 29, 2018
  • Post category:Drug Industry Daily

FDA Commissioner Scott Gottlieb Wednesday said the agency plans to scrap its existing guidance on developing new pain drugs and replace it with guidances designed to promote development of new…

Continue ReadingFDA to Replace Guidance on Developing New Pain Drugs

FDA Raps Ascend Therapeutics for Misleading Estrogel Claims

  • Post author:Sam
  • Post published:August 29, 2018
  • Post category:Drug Industry Daily

The FDA on Tuesday issued Ascend Therapeutics an untitled letter over misleading claims for its estrogen therapy Estrogel. Source: Drug Industry Daily

Continue ReadingFDA Raps Ascend Therapeutics for Misleading Estrogel Claims

FDA Invites Meeting Requests for Pilot Program to Spur Clinical Trial Innovation

  • Post author:Sam
  • Post published:August 29, 2018
  • Post category:Drug Industry Daily

Drug sponsors wishing to take part in the FDA’s pilot meeting program to discuss complex innovative trial designs (CIDs) with agency staff may now file meeting requests. Source: Drug Industry…

Continue ReadingFDA Invites Meeting Requests for Pilot Program to Spur Clinical Trial Innovation

Pfizer Calls for Guidance on Misleading Biosimilar-Related Communications

  • Post author:Sam
  • Post published:August 28, 2018
  • Post category:Drug Industry Daily

In a citizen petition filed Monday, Pfizer asked the FDA to issue draft guidance to prevent misleading communications by reference drug sponsors on the effectiveness of biosimilars. Source: Drug Industry…

Continue ReadingPfizer Calls for Guidance on Misleading Biosimilar-Related Communications

Seattle Compounder Warned Over Sterility Issues

  • Post author:Sam
  • Post published:August 28, 2018
  • Post category:Drug Industry Daily

Compounding pharmacy Kelley-Ross & Associates in Seattle drew a warning letter from the FDA after an agency inspection in July found numerous sanitation violations. Source: Drug Industry Daily

Continue ReadingSeattle Compounder Warned Over Sterility Issues
  • 1
  • 2
  • 3
  • 4
  • …
  • 11
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:
6042 Cornerstone Court W
Suite E
San Diego, CA 92121
Social::
© 2025 BioLegacy Research. All rights reserved.
BioLegacy research is a PharmaLegacy Laboratories company